- Home
- ONCO vs ACON Comparison
ONCO vs ACON Comparison
Compare ONCO & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | ACON |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.4M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ONCO | ACON |
|---|---|---|
| Price | $1.89 | $5.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 39.7K | ★ 66.3K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,223,751.00 | $67,483.00 |
| Revenue This Year | N/A | $145.39 |
| Revenue Next Year | N/A | $145.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.91 |
| 52 Week Low | $1.90 | $5.55 |
| 52 Week High | $179.35 | $3,499.49 |
Technical Indicators
Market Signals| Indicator | ONCO | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 34.05 | 42.43 |
| Support Level | $2.53 | $5.75 |
| Resistance Level | $3.22 | $6.89 |
| Average True Range (ATR) | 0.32 | 0.62 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 7.14 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.